Related references
Note: Only part of the references are listed.Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis
Kabirraaj Toor et al.
BMC CANCER (2021)
Systemic Therapy for Melanoma: ASCO Guideline
Rahul Seth et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma
Matthew Hemstock et al.
EUROPEAN JOURNAL OF CANCER (2020)
Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors
Elisabeth Coart et al.
EUROPEAN JOURNAL OF CANCER (2020)
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Corneel Coens et al.
LANCET ONCOLOGY (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Share Paper
